Get the Stockscreener App
6.315
4.21%
0.255
Alumis Inc stock is traded at $6.315, with a volume of 1.28M.
It is up +4.21% in the last 24 hours and down -24.82% over the past month.
Alumis Inc is a clinical-stage biopharmaceutical company with an initial focus on developing its two Tyrosine Kinase 2 ("TYK2") inhibitors: envudeucitinib ("envu"), an allosteric TYK2 inhibitor for the treatment of PsO and SLE; and A-005, a central nervous system ("CNS") penetrant allosteric TYK2 inhibitor, to offer the therapeutic benefit of TYK2 inhibition within the CNS for a broad range of neuroinflammatory and neurodegenerative diseases.
See More
Previous Close:
$6.06
Open:
$6.11
24h Volume:
1.28M
Relative Volume:
0.57
Market Cap:
$817.38M
Revenue:
$8.40M
Net Income/Loss:
$-237.42M
P/E Ratio:
-3.2868
EPS:
-1.9213
Net Cash Flow:
$-377.03M
1W Performance:
-9.40%
1M Performance:
-24.82%
6M Performance:
-73.86%
1Y Performance:
+30.21%
1-Day Range:
$6.08
$6.50
1-Week Range:
$6.015
$7.31
52-Week Range:
$4.37
$31.35
Alumis Inc Stock (ALMS) Company Profile
Name
Alumis Inc
Sector
Industry
Phone
650-231-6625
Address
280 EAST GRAND AVENUE, SOUTH SAN FRANCISCO
Compare ALMS vs VRTX, MRNA, REGN, ARGX, ONC
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
ALMS
Alumis Inc
|
6.315 | 817.38M | 8.40M | -237.42M | -377.03M | -1.9213 |
VRTX
Vertex Pharmaceuticals Inc
|
510.25 | 129.33B | 12.34B | 4.34B | 3.71B | 16.87 |
MRNA
Moderna Inc
|
237.99 | 95.01B | 2.23B | -3.19B | -1.60B | -8.1462 |
REGN
Regeneron Pharmaceuticals Inc
|
801.45 | 82.51B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
849.45 | 53.42B | 4.16B | 1.29B | 734.26M | 19.58 |
ONC
Beone Medicines Ltd Adr
|
372.00 | 42.08B | 5.76B | 514.49M | 1.10B | 4.4813 |
Alumis Inc Stock (ALMS) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Sep-03-26 | Downgrade | Guggenheim | Buy → Neutral |
| Sep-02-26 | Upgrade | H.C. Wainwright | Neutral → Buy |
| May-15-26 | Downgrade | H.C. Wainwright | Buy → Neutral |
| Mar-11-26 | Initiated | Raymond James | Strong Buy |
| Feb-25-26 | Initiated | Stifel | Buy |
| Jan-21-26 | Initiated | Chardan Capital Markets | Buy |
| Jul-25-25 | Initiated | Wells Fargo | Overweight |
| Jun-10-25 | Resumed | Guggenheim | Buy |
| Jan-30-25 | Initiated | Oppenheimer | Outperform |
| Oct-31-24 | Initiated | Robert W. Baird | Outperform |
| Oct-17-24 | Initiated | H.C. Wainwright | Buy |
| Jul-23-24 | Initiated | Cantor Fitzgerald | Overweight |
| Jul-23-24 | Initiated | Guggenheim | Buy |
| Jul-23-24 | Initiated | Leerink Partners | Outperform |
| Jul-23-24 | Initiated | Morgan Stanley | Overweight |
View All
Alumis Inc Stock (ALMS) Latest News
Alumis (Nasdaq:ALMS)Stock Analysis - simplywall.st
Why is Alumis stock rallying today? By Investing.com - Investing.com India
Why is Alumis stock rallying today? By Investing.com - Investing.com Canada
Alumis Insider Bought Shares Worth $10,726,255, According to a Recent SEC Filing - marketscreener.com
Wednesday’s top insider buys and sells: NVIDIA leads activity - Investing.com
Alumis director Akkaraju buys $5.8m, sells $1m of ALMS shares - Investing.com Australia
Alumis at Cantor conference: psoriasis strength, lupus setback - investing.com
Alumis director Akkaraju buys $5.8m, sells $1m of ALMS shares - Investing.com Canada
Alumis director Akkaraju buys $5.8m, sells $1m of ALMS shares - Investing.com
Alumis director Akkaraju buys $5.8m, sells $1m of ALMS shares - Investing.com
Alumis at Cantor conference: psoriasis strength, lupus setback By Investing.com - Investing.com Canada
Alumis (NASDAQ: ALMS) director buys 986K shares, agrees to give back trade profit - Stock Titan
Alumis (ALMS) Plans to Advance Envudeucitinib After LUMUS Missed in the Overall Population - Yahoo Finance
Alumis at Wells Fargo conference: lupus setback sharpens strategy By Investing.com - Investing.com Canada
Alumis at Wells Fargo conference: lupus setback sharpens strategy By Investing.com - Investing.com India
Alumis at Wells Fargo conference: lupus setback sharpens strategy By Investing.com - Investing.com UK
Price-Driven Insight from (ALMS) for Rule-Based Strategy - Stock Traders Daily
Alumis Inc. (ALMS) Discusses Phase IIb LUMUS Trial Results and Subgroup Insights in Type 1 Interferon-Driven DiseasesSlideshow (NASDAQ:ALMS) 2026-09-04 - Seeking Alpha
Alumis to Participate in Upcoming September Investor Conferences - The Manila Times
Four public talks are planned for September. Alumis will stream them online. - Stock Titan
Is Alumis (ALMS) Overvalued After Its 121% One Year Return? - Yahoo Finance
Alumis stock downgraded at Guggenheim (ALMS:NASDAQ) - Seeking Alpha
Why Alumis (ALMS) Is Down 56.2% After Mixed Phase 2b Lupus Data Spotlight Biomarker Strategy - finance.yahoo.com
Guggenheim Downgrades Alumis to Neutral From Buy - marketscreener.com
Alumis (ALMS) Looks Pricey After Its Lupus Trial Miss But Is 3x P B Fair? - Yahoo Finance
Alumis (ALMS) Lead Lupus Drug Missed Phase 2b Trial Endpoints - Yahoo Finance
Guggenheim downgrades Alumis stock rating after trial miss By Investing.com - Investing.com Canada
Guggenheim downgrades Alumis stock rating after trial miss By Investing.com - Investing.com Nigeria
Guggenheim downgrades Alumis stock rating after trial miss By Investing.com - Investing.com Australia
Guggenheim downgrades Alumis stock rating after trial miss By Investing.com - Investing.com India
Guggenheim downgrades Alumis stock rating after trial miss - investing.com
Guggenheim downgrades Alumis stock rating after trial miss By Investing.com - Investing.com UK
Morgan Stanley cuts Alumis stock price target on lupus trial failure By Investing.com - Investing.com South Africa
Alumis (ALMS) Stock Slides As Momentum Traders Refocus On Fundamentals - timothysykes.com
Alumis' Share Price Fall After Envudeucitinib Trial Data Likely Overreaction, Oppenheimer Says - marketscreener.com
This OGE Energy Analyst Turns Bullish; Here Are Top 4 Upgrades For Wednesday - Benzinga
Oppenheimer Adjusts Price Target on Alumis to $37 From $55, Maintains Outperform Rating - marketscreener.com
Morgan Stanley cuts Alumis stock price target on lupus trial failure - Investing.com India
Wells Fargo cuts Alumis stock price target on SLE trial results - Investing.com Australia
Morgan Stanley cuts Alumis stock price target on lupus trial failure - Investing.com
Morgan Stanley cuts Alumis stock price target on lupus trial failure - Investing.com Australia
Morgan Stanley cuts Alumis stock price target on lupus trial failure - Investing.com Nigeria
Morgan Stanley cuts Alumis stock price target on lupus trial failure - Investing.com Canada
Morgan Stanley cuts Alumis stock price target on lupus trial failure - Investing.com UK
Wells Fargo cuts Alumis stock price target on SLE trial results - Investing.com Nigeria
Wells Fargo cuts Alumis stock price target on SLE trial results - Investing.com India
Wells Fargo cuts Alumis stock price target on SLE trial results By Investing.com - Investing.com South Africa
Wells Fargo cuts Alumis stock price target on SLE trial results - Investing.com
Wells Fargo cuts Alumis stock price target on SLE trial results - Investing.com UK
ALMS Stock Slides After IPO Spike As Traders Reset - StocksToTrade
Alumis Inc Stock (ALMS) Financials Data
Revenue
Net Income
Cash Flow
EPS
Alumis Inc Stock (ALMS) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| AKKARAJU SRINIVAS | Director |
Sep 08 '26 |
Sale |
10.55 |
96,131 |
1,014,028 |
2,025,493 |
| AKKARAJU SRINIVAS | Director |
Sep 04 '26 |
Buy |
11.17 |
440,140 |
4,917,684 |
4,711,801 |
| Pangali Sanam | Chief Legal Officer |
Aug 03 '26 |
Sale |
26.37 |
1,364 |
35,969 |
9,747 |
| Hardiman Roy C. | Chief Business & Strategy Ofcr |
Aug 03 '26 |
Sale |
26.37 |
2,692 |
70,988 |
207,746 |
| Goldstein David M | Chief Scientific Officer |
Aug 03 '26 |
Sale |
26.37 |
2,596 |
68,457 |
30,970 |
| Drappa Jorn | Chief Medical Officer |
Aug 03 '26 |
Sale |
26.37 |
2,447 |
64,527 |
56,892 |
| Bradley Mark Christopher | Chief Development Officer |
Aug 03 '26 |
Sale |
26.37 |
2,572 |
67,824 |
48,533 |
| Schroer John R. | Chief Financial Officer |
Aug 03 '26 |
Sale |
26.37 |
3,282 |
86,546 |
24,718 |
| SANAMPREET PANGALI | Officer |
Jul 06 '26 |
Proposed Sale |
28.00 |
5,000 |
140,000 |
0 |
| Pangali Sanam | Chief Legal Officer |
Jul 06 '26 |
Option Exercise |
5.06 |
5,000 |
25,300 |
16,111 |
3.33%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):